Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
23.04.2025 11:07:00
|
Is Eli Lilly Stock a Buy?
Type 2 diabetes and obesity have become an increasing global healthcare problem, reaching near crisis proportions in the United States. The arrival of GLP-1 agonists, drugs that mimic hormones to slow digestion and quell hunger, offers a potential solution and has created one of the pharmaceutical industry's most lucrative opportunities in recent history.Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales of GLP-1 agonists could grow at a 33% annualized rate, reaching $471 billion by 2032.Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 710,50 | 1,79% |
|